Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 9/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.37 |
| ▸ | HTR3B | O95264 | 3/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.37 |
| ▸ | HTR5A | P47898 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13849261 | 0.85 | CHRNA7 (0.42) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL13849258 | 0.85 | CHRNA7 (0.42) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL13849264 | 0.82 | FLT3 (0.42) | — | |
| SCHEMBL13849260 | 0.81 | CHRNA7 (0.43) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL13849257 | 0.80 | CHEK1 (0.46) | HTR3ACHRNA7TSHRHTR3EHTR3B | |
| SCHEMBL4091122 | 0.74 | SIRT2 (0.41) | ALDH1A1KMT2A | |
| SCHEMBL13849200 | 0.73 | FLT3 (0.45) | — | |
| SCHEMBL5650989 | 0.71 | CHRNA7 (0.57) | HTR3ACHRNA7TSHRHTR3EHTR3B | |
| SCHEMBL5952481 | 0.71 | CHEK1 (0.48) | ALDH1A1 | |
| SCHEMBL13849221 | 0.70 | CHEK1 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | PDK1, CHEK1, PDK3 | HTR3A 2722/4885CHRNA7 1023/4885CYP2C9 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.